Authors:
AP Sokolenko, DR Bulanova, AG Iyevleva, SN Aleksakhina, EV Preobrazhenskaya, AO Ivantsov, ES Kuligina, NV Mitiushkina, EN Suspitsin, GA Yanus, OA Zaitseva, OS Yatsuk, AV Togo, P Kota, JM Dixon, AA Larionov, SG Kuznetsov, EN Imyanitov
Journal name: 
Int J Cancer
Citation info: 
134(10):2352-2358
Abstract: 
In a search for new breast cancer (BC) predisposing genes, we performed a whole exome sequencing analysis using six patient samples of familial BC and identified a germline inactivating mutation c.183delG [p. Arg61fs] in an orphan G protein-coupled receptor GPRC5A. An extended case-control study revealed a tenfold enrichment for this mutation in BC patients carrying the 5382insC allele of BRCA1, the major founder mutation in the Russian population, compared to wild-type BRCA1 BC cases [6/117 (5.1%) vs. 8/1578 (0.5%), p = 0.0002]. In mammary tumors (n = 60), the mRNA expression of GPRC5A significantly correlated with that of BRCA1 (p = 0.00018). In addition, the amount of GPRC5A transcript was significantly lower in BC obtained from BRCA1 mutation carriers (n = 17) compared to noncarriers (n = 93) (p = 0.026). Accordingly, a siRNA-mediated knockdown of either BRCA1 or GPRC5A in the MDA-MB-231 human BC cell line reduced expression of GPRC5A or BRCA1, respectively. Knockdown of GPRC5A also attenuated radiation-induced BRCA1- and RAD51-containing nuclear DNA repair foci. Taken together, these data suggest that GPRC5A is a modifier of BC risk in BRCA1 mutation carriers and reveals a functional interaction of these genes.
DOI: 
http://doi.org/10.1002/ijc.28569
E-pub date: 
15 May 2014